知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.04 秒)

    Oligonucleotides specific for the marORAB operon
    1.
    发明授权
    Oligonucleotides specific for the marORAB operon 失效
    特异于marORAB操纵子的寡核苷酸

    公开(公告)号：US06485973B1

    公开(公告)日：2002-11-26

    申请号：US09596390

    申请日：2000-06-16

    申请人： Stuart B. Levy ,  Eric Von Hofe

    发明人： Stuart B. Levy ,  Eric Von Hofe

    IPC分类号： C07H2104

    CPC分类号： C12N15/113 ,  A61K38/00 ,  C12N2310/111 ,  C12N2310/315 ,  Y02A50/475 ,  Y02A50/481

    摘要： Disclosed are synthetic oligonucleotides complementary to a transcript of the marORAB operon which inhibit expression of a gene in the operon. Also disclosed are methods of reducing bacterial resistance to antibiotics, and pharmaceutical formulations containing marORAB-specific oligonucleotides of the invention.

    摘要翻译： 公开了与抑制操纵子中基因表达的marORAB操纵子的转录物互补的合成寡核苷酸。 还公开了减少细菌抗生素抗性的方法，以及含有本发明的marORAB特异性寡核苷酸的药物制剂。

    Reducing Tetracycline Resistance in Living Cells
    4.
    发明申请
    Reducing Tetracycline Resistance in Living Cells 失效
    减少活细胞中的四环素抗性

    公开(公告)号：US20090131696A1

    公开(公告)日：2009-05-21

    申请号：US12194362

    申请日：2008-08-19

    申请人： Stuart B. Levy

    发明人： Stuart B. Levy

    IPC分类号： C07C237/26

    CPC分类号： C07D295/13 ,  A61K31/65 ,  C07C237/26 ,  C07C323/29 ,  C07C2601/08 ,  A61K2300/00

    摘要： The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

    摘要翻译： 本发明提供了一种改进的方法，其通过其治疗来克服包括细菌，寄生虫，真菌和立克次体在内的活细胞中对四环素的抗性。 该方法采用封闭剂如C5酯衍生物或四环素的6-脱氧13-（取代的巯基）衍生物与其他四环素型抗生素组合，作为同时，顺序或同时施用的组合物的协同组合。 在另一个实施方案中，提供某些新的组合物，其可以针对例如革兰氏阳性细菌如金黄色葡萄球菌和粪肠球菌的敏感或抗性菌株单独施用。 伴随施用的组合物有效克服存在的四环素抗性机制，使得细胞有效地从四环素抗性状态转变为四环素敏感状态。

    Reducing tetracycline resistance in living cells
    6.
    发明授权
    Reducing tetracycline resistance in living cells 失效
    减少活细胞中四环素的耐药性

    公开(公告)号：US07414041B2

    公开(公告)日：2008-08-19

    申请号：US10770883

    申请日：2004-02-02

    申请人： Stuart B. Levy

    发明人： Stuart B. Levy

    IPC分类号： A61K31/65

    CPC分类号： C07D295/13 ,  A61K31/65 ,  C07C237/26 ,  C07C323/29 ,  C07C2601/08 ,  A61K2300/00

    摘要： The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

    摘要翻译： 本发明提供了一种改进的方法，其通过其治疗来克服包括细菌，寄生虫，真菌和立克次体在内的活细胞中对四环素的抗性。 该方法采用封闭剂如C5酯衍生物或四环素的6-脱氧13-（取代的巯基）衍生物与其他四环素型抗生素组合，作为同时，顺序或同时施用的组合物的协同组合。 在另一个实施方案中，提供某些新的组合物，其可以针对例如革兰氏阳性细菌如金黄色葡萄球菌和粪肠球菌的敏感或抗性菌株单独施用。 伴随施用的组合物有效克服存在的四环素抗性机制，使得细胞有效地从四环素抗性状态转变为四环素敏感状态。

    Reducing tetracycline resistance in living cells
    8.
    发明授权
    Reducing tetracycline resistance in living cells 失效
    减少活细胞中四环素的耐药性

    公开(公告)号：US5589470A

    公开(公告)日：1996-12-31

    申请号：US232247

    申请日：1994-06-14

    申请人： Stuart B. Levy

    发明人： Stuart B. Levy

    IPC分类号： A61K31/65 ,  C07C237/26 ,  C07C323/29 ,  C07D295/13

    CPC分类号： C07D295/13 ,  A61K31/65 ,  C07C237/26 ,  C07C323/29 ,  C07C2101/08

    摘要： The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, C5 ester novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

    摘要翻译： PCT No.PCT / US92 / 08965 Sec。 371日期：1994年6月14日 102（e）日期1994年6月14日PCT提交于1992年10月16日PCT公布。 出版物WO93 / 08806 日期1993年5月13日本发明提供了一种改进的方法，其通过治疗来克服对包括细菌，寄生虫，真菌和立克次体在内的活细胞中的四环素的抗性。 该方法采用封闭剂如C5酯衍生物或四环素的13-（取代的巯基）衍生物与其它四环素型抗生素组合，作为同时，顺序或同时施用的组合物的协同组合。 在另一个实施方案中，提供C5酯新组合物，其可以单独施用于例如革兰氏阳性细菌如金黄色葡萄球菌和粪肠球菌的敏感或抗性菌株。 伴随施用的组合物有效克服存在的四环素抗性机制，使得细胞有效地从四环素抗性状态转变为四环素敏感状态。

    Method and compositions for overcoming tetracycline resistance within living cells
    9.
    发明授权
    Method and compositions for overcoming tetracycline resistance within living cells 失效
    克服活细胞内四环素抗性的方法和组合物

    公开(公告)号：US5064821A

    公开(公告)日：1991-11-12

    申请号：US484904

    申请日：1990-02-26

    申请人： Stuart B. Levy

    发明人： Stuart B. Levy

    IPC分类号： A61K31/65

    CPC分类号： A61K31/65

    摘要： The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs 13-(substituted mercapto) derivatives of tetracycline in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously or concurrently. The concomittantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state. The combination also effects a synergistic bacteriocidal activity against susceptible and resistant cells.

    摘要翻译： 本发明提供了一种改进的方法，其通过其治疗来克服包括细菌，寄生虫，真菌和立克次体在内的活细胞中对四环素的抗性。 该方法使用四环素的13-（取代的巯基）衍生物与其他四环素型抗生素组合作为同时或同时施用的组合物的协同组合。 相应地施用的组合物有效克服存在的四环素抗性机制，使得细胞有效地从四环素耐受状态转变为四环素敏感状态。 该组合还对易感和抗性细胞产生协同杀菌活性。